209 related articles for article (PubMed ID: 19622750)
1. Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.
Tchesnokov EP; Obikhod A; Schinazi RF; Götte M
J Biol Chem; 2009 Sep; 284(39):26439-46. PubMed ID: 19622750
[TBL] [Abstract][Full Text] [Related]
2. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
3. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.
Tchesnokov EP; Gilbert C; Boivin G; Götte M
J Virol; 2006 Feb; 80(3):1440-50. PubMed ID: 16415021
[TBL] [Abstract][Full Text] [Related]
4. Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase.
Zahn KE; Tchesnokov EP; Götte M; Doublié S
J Biol Chem; 2011 Jul; 286(28):25246-55. PubMed ID: 21566148
[TBL] [Abstract][Full Text] [Related]
5. Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases.
Zarrouk K; Zhu X; Goyette N; Piret J; Shi R; Boivin G
Antiviral Res; 2021 Apr; 188():105046. PubMed ID: 33588012
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet.
Ducancelle A; Alain S; Petit F; Sanson Le Pors MJ; Mazeron MC
J Virol Methods; 2007 May; 141(2):212-5. PubMed ID: 17197042
[TBL] [Abstract][Full Text] [Related]
7. Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Andouard D; Mazeron MC; Ligat G; Couvreux A; Pouteil-Noble C; Cahen R; Yasdanpanah Y; Deering M; Viget N; Alain S; Hantz S
Antiviral Res; 2016 May; 129():115-119. PubMed ID: 26872863
[TBL] [Abstract][Full Text] [Related]
8. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
9. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S
Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Chou S
J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
[TBL] [Abstract][Full Text] [Related]
11. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Cihlar T; Fuller MD; Cherrington JM
J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
[TBL] [Abstract][Full Text] [Related]
12. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
13. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers.
Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM
mBio; 2021 Feb; 12(1):. PubMed ID: 33563814
[TBL] [Abstract][Full Text] [Related]
14. Effects of Acyclovir, Foscarnet, and Ribonucleotides on Herpes Simplex Virus-1 DNA Polymerase: Mechanistic Insights and a Novel Mechanism for Preventing Stable Incorporation of Ribonucleotides into DNA.
Vashishtha AK; Kuchta RD
Biochemistry; 2016 Feb; 55(7):1168-77. PubMed ID: 26836009
[TBL] [Abstract][Full Text] [Related]
15. Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet.
Zarrouk K; Zhu X; Pham VD; Goyette N; Piret J; Shi R; Boivin G
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0039021. PubMed ID: 33875432
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
17. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase.
Mousavi-Jazi M; Schloss L; Wahren B; Brytting M
J Clin Virol; 2003 Apr; 26(3):301-6. PubMed ID: 12637079
[TBL] [Abstract][Full Text] [Related]
18. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.
Gilbert C; Azzi A; Goyette N; Lin SX; Boivin G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4019-27. PubMed ID: 21709106
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.
Loregian A; Rigatti R; Murphy M; Schievano E; Palu G; Marsden HS
J Virol; 2003 Aug; 77(15):8336-44. PubMed ID: 12857903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
